[{"address1": "Wallstrasse 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "fax": "49 89 2153 90351", "website": "https://www.atai.life", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder & CEO", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 793650, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 494232, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.35, "open": 1.36, "dayLow": 1.34, "dayHigh": 1.4, "regularMarketPreviousClose": 1.35, "regularMarketOpen": 1.36, "regularMarketDayLow": 1.34, "regularMarketDayHigh": 1.4, "payoutRatio": 0.0, "beta": 1.186, "forwardPE": -2.037206, "volume": 1033125, "regularMarketVolume": 1033125, "averageVolume": 2879420, "averageVolume10days": 1593580, "averageDailyVolume10Day": 1593580, "bid": 1.35, "ask": 1.43, "bidSize": 1, "askSize": 1, "marketCap": 268738496, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 2.85, "priceToSalesTrailing12Months": 872.5276, "fiftyDayAverage": 1.7221, "twoHundredDayAverage": 1.437275, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 179593584, "profitMargins": 0.0, "floatShares": 120761868, "sharesOutstanding": 193992992, "sharesShort": 10956604, "sharesShortPriorMonth": 11307134, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.056500003, "heldPercentInsiders": 0.08462, "heldPercentInstitutions": 0.29189, "shortRatio": 2.38, "shortPercentOfFloat": 0.071, "impliedSharesOutstanding": 193992992, "bookValue": 0.724, "priceToBook": 1.9133979, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -149268992, "trailingEps": -0.93, "forwardEps": -0.68, "enterpriseToRevenue": 583.096, "enterpriseToEbitda": -1.755, "52WeekChange": -0.20588237, "SandP52WeekChange": 0.07465422, "quoteType": "EQUITY", "currentPrice": 1.3853, "targetHighPrice": 11.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 62330000, "totalCashPerShare": 0.388, "ebitda": -102360336, "totalDebt": 24706000, "quickRatio": 2.498, "currentRatio": 3.211, "totalRevenue": 308000, "debtToEquity": 21.197, "revenuePerShare": 0.002, "returnOnAssets": -0.28345, "returnOnEquity": -0.8316, "grossProfits": 308000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": 6053.0, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "ATAI Life Sciences N.V.", "regularMarketChangePercent": 2.6059365, "regularMarketPrice": 1.3853, "corporateActions": [], "regularMarketTime": 1742412362, "messageBoardId": "finmb_710359021", "longName": "Atai Life Sciences N.V.", "marketState": "REGULAR", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "regularMarketChange": 0.035300016, "regularMarketDayRange": "1.34 - 1.4", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2879420, "fiftyTwoWeekLowChange": 0.35530007, "fiftyTwoWeekLowChangePercent": 0.34495154, "fiftyTwoWeekRange": "1.03 - 2.85", "fiftyTwoWeekHighChange": -1.4646999, "fiftyTwoWeekHighChangePercent": -0.5139298, "fiftyTwoWeekChangePercent": -20.588238, "earningsTimestamp": 1742214600, "earningsTimestampStart": 1747133940, "earningsTimestampEnd": 1747656000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.93, "epsForward": -0.68, "epsCurrentYear": -0.82333, "priceEpsCurrentYear": -1.6825575, "fiftyDayAverageChange": -0.33679998, "fiftyDayAverageChangePercent": -0.19557516, "twoHundredDayAverageChange": -0.05197501, "twoHundredDayAverageChangePercent": -0.03616219, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.3 - Strong Buy", "exchange": "NGM", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Atai Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-03-19"}]